<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="case-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">66TJ9rfr9rWG9tsgdmYT4Wq</article-id>
      <article-id pub-id-type="other">00024</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010000400024</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09400424</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010000400024</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato de Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Associa&#231;&#227;o de bronquite pl&#225;stica com enteropatia perdedora de prote&#237;nas ap&#243;s opera&#231;&#227;o de Fontan</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Guimar&#227;es</surname>
            <given-names>Vanessa Alves</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Atik</surname>
            <given-names>Edmar</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Castelli</surname>
            <given-names>Jussara Bianchi</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ikari</surname>
            <given-names>Nana Miura</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thomaz</surname>
            <given-names>Ana Maria</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lopes</surname>
            <given-names>Antonio Augusto Barbosa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <institution content-type="orgdiv2">Hospital das Cl&#237;nicas</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>04</month>
        <year>2010</year>
      </pub-date>
      <volume>94</volume>
      <issue>4</issue>
      <fpage>e109</fpage>
      <lpage>e112</lpage>
      <history>
        <date date-type="accepted">
          <day>01</day>
          <month>09</month>
          <year>2009</year>
        </date>
        <date date-type="rev-recd">
          <day>23</day>
          <month>03</month>
          <year>2009</year>
        </date>
        <date date-type="received">
          <day>02</day>
          <month>12</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Relatamos um caso incomum de associa&#231;&#227;o de bronquite pl&#225;stica (BP) com enteropatia perdedora de prote&#237;nas (EPP) em menina de 4 anos e 9 meses de idade. com dupla via de entrada de ventr&#237;culo &#250;nico tipo esquerdo e concord&#226;ncia ventr&#237;culo-arterial submetida &#224; cirurgia cavopulmonar total. com t&#250;nel lateral intracard&#237;aco aos tr&#234;s anos. Tornaram-se chamativas a elimina&#231;&#227;o de molde br&#244;nquico de fibrina de 10 cm (BP) e a eleva&#231;&#227;o de alfa-1-antitripsina de 52 mg/g de fezes. Em uso de sildenafila. programou-se. em caso de continuidade do processo. a ligadura do ducto tor&#225;cico e transplante card&#237;aco.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>T&#233;cnica de Fontan</kwd>
        <kwd>bronquite</kwd>
        <kwd>enteropatias perdedoras de prote&#237;nas</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>22</day>
        <month>09</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>RELATO DE CASO</bold>
    </p>
    <p>Associa&#231;&#227;o de bronquite pl&#225;stica com enteropatia perdedora de prote&#237;nas ap&#243;s opera&#231;&#227;o de Fontan</p>
    <p>
      <bold>Vanessa Alves Guimar&#227;es; Edmar Atik; Jussara Bianchi Castelli; Nana Miura Ikari; Ana Maria Thomaz; Antonio Augusto Barbosa Lopes</bold>
    </p>
    <p>Instituto do Cora&#231;&#227;o (InCor). Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo. S&#227;o Paulo. SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="linkcorresp">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p>Relatamos um caso incomum de associa&#231;&#227;o de bronquite pl&#225;stica (BP) com enteropatia perdedora de prote&#237;nas (EPP) em menina de 4 anos e 9 meses de idade. com dupla via de entrada de ventr&#237;culo &#250;nico tipo esquerdo e concord&#226;ncia ventr&#237;culo-arterial submetida &#224; cirurgia cavopulmonar total. com t&#250;nel lateral intracard&#237;aco aos tr&#234;s anos. Tornaram-se chamativas a elimina&#231;&#227;o de molde br&#244;nquico de fibrina de 10 cm (BP) e a eleva&#231;&#227;o de alfa-1-antitripsina de 52 mg/g de fezes. Em uso de sildenafila. programou-se. em caso de continuidade do processo. a ligadura do ducto tor&#225;cico e transplante card&#237;aco.</p>
    <p><bold>Palavras-chave:</bold> T&#233;cnica de Fontan. bronquite. enteropatias perdedoras de prote&#237;nas.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A opera&#231;&#227;o de Fontan. embora seja a melhor palia&#231;&#227;o para cora&#231;&#245;es univentriculares. acompanha-se na evolu&#231;&#227;o de graves complica&#231;&#245;es. como a bronquite pl&#225;stica (BP) e a enteropatia perdedora de prote&#237;nas (EPP). al&#233;m de outras comorbidades<sup>1</sup>. Estima-se que a EPP incida em uma percentagem vari&#225;vel de cerca de 1%-13.4%<sup>2.3</sup>. A ocorr&#234;ncia de BP &#233; relatada<sup>4-6</sup> muito raramente. assim como a associa&#231;&#227;o dessas duas entidades<sup>5</sup>. Por isso. &#233; nosso prop&#243;sito relatar essa rara associa&#231;&#227;o.</p>
    <p>
      <bold>Relato do caso</bold>
    </p>
    <p>Uma paciente do sexo feminino. com 4 anos e 9 meses de idade. natural e procedente de S&#227;o Paulo-SP. nascida de parto normal. a termo. sendo filha de m&#227;e diab&#233;tica. apresentou desconforto respirat&#243;rio precoce e sopro card&#237;aco auscultado na primeira semana de vida. Na &#233;poca. estabeleceu-se o diagn&#243;stico de dupla via de entrada de ventr&#237;culo &#250;nico tipo esquerdo com concord&#226;ncia ventr&#237;culo-arterial. comunica&#231;&#227;o interatrial (CIA). comunica&#231;&#227;o interventricular e persist&#234;ncia de canal arterial (CA). com hipertens&#227;o pulmonar importante. Com um m&#234;s de vida. foi submetida. em nosso servi&#231;o e com sucesso. &#224; amplia&#231;&#227;o da CIA pelo m&#233;todo de Rashkind e. ap&#243;s 4 dias. &#224; bandagem do tronco pulmonar e fechamento do CA. Aos tr&#234;s anos e 4 meses. houve acentua&#231;&#227;o da cianose e da dispneia.</p>
    <p>O estudo hemodin&#226;mico demonstrou press&#227;o m&#233;dia de 13 mmHg na art&#233;ria pulmonar. press&#227;o m&#233;dia de 10 mmHg no capilar pulmonar. com Qp/Qs = 0.9 e resist&#234;ncia vascular pulmonar de 1.7 UW. A seguir. foi submetida &#224; opera&#231;&#227;o cavopulmonar total com t&#250;nel lateral intracard&#237;aco. Ap&#243;s tr&#234;s meses da interven&#231;&#227;o. apresentou-se com anasarca. ascite e derrame pleural. A albumina s&#233;rica era de 1.7 mg/dl. Por estudo hemodin&#226;mico. descartou-se obstru&#231;&#227;o ao fluxo venoso sangu&#237;neo. A press&#227;o m&#233;dia da art&#233;ria pulmonar. da veia cava superior e da veia cava inferior era de 15 mmHg. a press&#227;o capilar pulmonar era de 7 mmHg e o Qp/Qs era de 0.8. </p>
    <p>O resultado da pesquisa de alfa-1-antitripsina nas fezes foi de 52 mg/g. confirmando o diagn&#243;stico de EPP. Com as medidas usuais. dieta hiperproteica. hipogordurosa e com triglic&#233;rides de cadeia m&#233;dia ao lado de anticongestivos. como furosemida. espironolactona e captopril. houve melhora do quadro. conseguindo-se at&#233; a normalidade de alfa-1-antitripsina (menor do que 3 mg/g). Ap&#243;s 14 meses da opera&#231;&#227;o. houve nova piora do quadro de anasarca. al&#233;m de tosse incessante. aparecimento de cianose e pico febril. A albumina s&#233;rica era de 2.1 mg/dl e a alfa-1-antitripsina de 13.2 mg/g. O quadro cl&#237;nico melhorou com medidas anticongestivas usuais em poucos dias.</p>
    <p>Incidentalmente. durante os exerc&#237;cios de fisioterapia respirat&#243;ria. a paciente expeliu molde br&#244;nquico de fibrina. com cerca de 10 cm de comprimento (<xref ref-type="fig" rid="a24fig01">Figura 1</xref>). Na radiografia de t&#243;rax. havia infiltrado peri-hilar. e na tomografia computadorizada de t&#243;rax de alta resolu&#231;&#227;o. imagem hipoatenuante na luz br&#244;nquica (<xref ref-type="fig" rid="a24fig01">Figura 1</xref>). O laudo anatomopatol&#243;gico do material br&#244;nquico era compat&#237;vel com o diagn&#243;stico de BP. j&#225; que se constitu&#237;a de fibrina compactada e entremeada por numerosas c&#233;lulas linfoides. com &#225;reas ainda de tecido mucoide escasso e permeado por macr&#243;fagos xantomatosos. al&#233;m de &#225;rea focal com ac&#250;mulo de eosin&#243;filos (<xref ref-type="fig" rid="a24fig02">Figura 2</xref>). </p>
    <p content-type="asset">
      <fig id="a24fig01">
        <graphic xlink:href="1678-4170-abc-94-04-e109-00024-gf01.jpg"/></fig>
    </p>
    <p content-type="asset">
      <fig id="a24fig02">
        <graphic xlink:href="1678-4170-abc-94-04-e109-00024-gf02.jpg"/></fig>
    </p>
    <p>Microscopia e imuno-histoqu&#237;mica exclu&#237;ram causas infecciosas (bact&#233;rias. bacilos &#225;lcool-&#225;cido resistentes. v&#237;rus e fungos). A partir do diagn&#243;stico estabelecido da associa&#231;&#227;o da BP &#224; EPP. foram institu&#237;das medidas cl&#237;nicas de fluidifica&#231;&#227;o de vias a&#233;reas com inala&#231;&#245;es e broncodilatadores. al&#233;m da furosemida. do captopril. da espironolactona e do sildenafil. Programou-se. em caso de continuidade do processo. a ligadura do ducto tor&#225;cico. culminando at&#233; com poss&#237;vel transplante card&#237;aco.</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Atualmente. os fatores envolvidos no progn&#243;stico evolutivo ap&#243;s a opera&#231;&#227;o de Fontan consistem na feitura de comunica&#231;&#227;o adequada entre as veias sist&#234;micas e a art&#233;ria pulmonar. sem obstru&#231;&#245;es e com m&#237;nima perda de energia. al&#233;m da coexist&#234;ncia de baixa resist&#234;ncia vascular pulmonar. bom desempenho ventricular. funcionamento normal das valvas atrioventriculares e tamanho normal da &#225;rvore arterial pulmonar. A opera&#231;&#227;o tem sofrido grandes modifica&#231;&#245;es t&#233;cnicas e. nos dias atuais. consiste predominantemente na conex&#227;o venosa sist&#234;mico-pulmonar realizada por tubo extracard&#237;aco. mais do que por t&#250;nel lateral intracard&#237;aco. com ou sem fenestra&#231;&#227;o. O resultado final deixa o paciente com duas circula&#231;&#245;es em s&#233;rie. sendo que o retorno venoso sist&#234;mico &#233; orientado diretamente para a art&#233;ria pulmonar sem a presen&#231;a da bomba puls&#225;til ventricular. Essa "fisiologia Fontan" submete os pacientes a um fluxo venoso mais lento. suscet&#237;vel assim ao desenvolvimento de efus&#227;o pleural cr&#244;nica. quilot&#243;rax. arritmias atriais. EPP e BP<sup>4</sup>.</p>
    <p>Quanto &#224; BP. constitui-se em rara entidade. &#201; caracterizada por expectora&#231;&#227;o recorrente de peculiares moldes da pr&#243;pria &#225;rvore traqueobr&#244;nquica. Embora sua etiopatogenia permane&#231;a desconhecida. a eleva&#231;&#227;o da press&#227;o venosa central e desordens do sistema linf&#225;tico pulmonar e sist&#234;mico s&#227;o prov&#225;veis mecanismos patog&#234;nicos<sup>5</sup>. Esses mesmos elementos correlacionam-se com a EPP. acrescido ao fato de que. cronicamente. o baixo d&#233;bito card&#237;aco contribuiria para o aumento da resist&#234;ncia vascular mesent&#233;rica. Assim. a associa&#231;&#227;o de hipoperfus&#227;o mesent&#233;rica com congest&#227;o venosa afetaria a integridade da mucosa intestinal. No caso apresentado. a paciente se mostrava com press&#227;o pulmonar normal. excluindo assim parte desse mecanismo patog&#234;nico.</p>
    <p>Usualmente. pacientes com BP apresentam dispneia com aumento do trabalho ventilat&#243;rio. epis&#243;dios de tosse repetitivos e elimina&#231;&#227;o dos moldes. com predisposi&#231;&#227;o a fen&#244;menos respirat&#243;rios. como infec&#231;&#227;o e atelectasias. Radiografias de t&#243;rax geralmente revelam um infiltrado peribr&#244;nquico. al&#233;m das atelectasias. Os moldes de secre&#231;&#227;o br&#244;nquica podem causar asfixia. parada card&#237;aca e morte. que tem sido relatada em at&#233; 29% dos pacientes com essa condi&#231;&#227;o latente<sup>6</sup>.</p>
    <p>Na EPP. em decorr&#234;ncia da perda ent&#233;rica de prote&#237;nas s&#233;ricas. h&#225; edema e m&#225; absor&#231;&#227;o na parede intestinal. ocasionando diarreia. Em alguns pacientes. esse processo &#233; mais insidioso e a hipoproteinemia pode ocorrer na aus&#234;ncia de sintomas diarreicos. A doen&#231;a tipicamente se inicia com edema corporal. evoluindo com ascite. efus&#227;o pleural e peric&#225;rdica. Os testes de laborat&#243;rio revelam baixos n&#237;veis de prote&#237;na s&#233;rica total e albumina. O <italic>gold standart</italic> para o diagn&#243;stico &#233; um <italic>clearance</italic> intestinal aumentado de alfa-1-antitripsina. prote&#237;na produzida exclusivamente no f&#237;gado e excretada em pequenas quantidades pelo intestino. A diminui&#231;&#227;o dos n&#237;veis s&#233;ricos de albumina reduz o transporte de c&#225;lcio. acarretando tetania e osteopenia. Outro dist&#250;rbio poss&#237;vel &#233; a hipogamaglobulinemia. acarretando imunodefici&#234;ncia. O in&#237;cio dessa enteropatia pode ter s&#233;rias consequ&#234;ncias. resultando no aumento de morbimortalidade. Dois estudos descrevem sobrevida em 5 anos. ap&#243;s o diagn&#243;stico de somente 50% dos pacientes<sup>3</sup>.</p>
    <p>Muitas vezes. o tratamento de ambas as condi&#231;&#245;es &#233; somente sintom&#225;tico. Na BP. pode ser de dois tipos: o tipo inflamat&#243;rio. secund&#225;rio a processos al&#233;rgicos expressivos. que pode ser manuseado com medica&#231;&#245;es inalat&#243;rias (corticosteroides. azitromicina. uroquinase); e o tipo acelular. prevalente ap&#243;s a opera&#231;&#227;o de Fontan. que tem se beneficiado da fenestra&#231;&#227;o do circuito. do uso de medica&#231;&#245;es hipotensoras pulmonares. da ligadura do ducto tor&#225;cico ou ent&#227;o do transplante card&#237;aco<sup>4.7-10</sup>. No tratamento da EPP. existe ainda o recurso de exclus&#227;o cir&#250;rgica das veias supra-hep&#225;ticas. O uso de heparina de baixo peso molecular tem sido descrito como curativo de ambas as entidades. sugerindo tratar-se da mesma fisiopatologia<sup>2</sup>. </p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="linkcorresp" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Edmar Atik </p>
        <p> Rua Dona Adma Jafet. 74 conj.73 - Bela Vista </p>
        <p> 01308-050 - S&#227;o Paulo. SP - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="eatik@cardiol.br">eatik@cardiol.br</email>. </p>
        <p>
          <email xlink:href="conatik@incor.usp.br">conatik@incor.usp.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 02/12/08; revisado recebido em 23/03/09; aceito em 01/09/09.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Camposilvan S. Milanesi O. Stellin G. Pettenazzo A. Zancan L. D&#226;Antiga L. Liver and cardiac function in the long term after Fontan operation. Ann Thorac Surg. 2008; 86 (1): 177-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>D&#226;&#8364;&#8482;Antiga L. Liver and cardiac function in the long term after Fontan operation</article-title>
          <source>Ann Thorac Surg</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>177</fpage>
          <lpage>82</lpage>
          <issue>1</issue>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Camposilvan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Milanesi</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Stellin</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pettenazzo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zancan</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Bhagirath KM. Tam JW. Resolution of protein-losing enteropathy with low-molecular weight heparin in an adult patient with Fontan palliation. Ann Thorac Surg. 2007; 84 (6): 2110-2.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Resolution of protein-losing enteropathy with low-molecular weight heparin in an adult patient with Fontan palliation</article-title>
          <source>Ann Thorac Surg</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>2110</fpage>
          <lpage>2</lpage>
          <issue>6</issue>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bhagirath</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Tam</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Rychik J. Protein-losing enteropathy after Fontan operation. Congenit Heart Dis. 2007; 2: 288-300.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Protein-losing enteropathy after Fontan operation</article-title>
          <source>Congenit Heart Dis</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>288</fpage>
          <lpage>300</lpage>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rychik</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Salman S. Shah A. Drinkwater DC. Christian KG. Plastic bronchitis: is thoracic duct ligation a real surgical option? Ann Thorac Surg. 2006; 81 (6): 2281-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plastic bronchitis: is thoracic duct ligation a real surgical option?</article-title>
          <source>Ann Thorac Surg</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>2281</fpage>
          <lpage>3</lpage>
          <issue>6</issue>
          <volume>81</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Salman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Drinkwater</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Christian</surname>
              <given-names>KG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Stiller B. Riedel F. Paul K. Van Landeghem FK. Plastic bronchitis in children with Fontan palliation: analogue to protein losing enteropathy? Pediatr Cardiol. 2002; 23: 90-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plastic bronchitis in children with Fontan palliation: analogue to protein losing enteropathy?</article-title>
          <source>Pediatr Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>90</fpage>
          <lpage>4</lpage>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stiller</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Riedel</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Van Landeghem</surname>
              <given-names>FK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Brogan TV. Finn LS. Pyskaty DJ Jr. Redding GJ. Ricker D. Inglis A. et al. Plastic bronchitis in children: a case series and review of the medical literature. Pediatr Pulmonol. 2002; 34 (6): 482-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plastic bronchitis in children: a case series and review of the medical literature</article-title>
          <source>Pediatr Pulmonol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>482</fpage>
          <lpage>7</lpage>
          <issue>6</issue>
          <volume>34</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brogan</surname>
              <given-names>TV</given-names>
            </name>
            <name>
              <surname>Finn</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Pyskaty</surname>
              <given-names>DJ Jr</given-names>
            </name>
            <name>
              <surname>Redding</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Ricker</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Inglis</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Wilson J. Russell J. Williams W. Benson L. Fenestration of the Fontan circuit as treatment for plastic bronchitis. Pediatr Cardiol. 2005; 26 (5): 717-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Fenestration of the Fontan circuit as treatment for plastic bronchitis</article-title>
          <source>Pediatr Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>717</fpage>
          <lpage>9</lpage>
          <issue>5</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wilson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Russell</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Benson</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Apostolopoulou SC. Papagiannis J. Rammos S. Bosentan induces clinical. exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. J Heart Lung Transplant. 2005; 24 (8): 1174-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Bosentan induces clinical: exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation</article-title>
          <source>J Heart Lung Transplant</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1174</fpage>
          <lpage>6</lpage>
          <issue>8</issue>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Apostolopoulou</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Papagiannis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rammos</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Haseyama K. Satomi G. Yasukochi S. Matsui H. Harada Y. Uchita S. Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 2006; 132 (5): 1232-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome</article-title>
          <source>J Thorac Cardiovasc Surg</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1232</fpage>
          <lpage>3</lpage>
          <issue>5</issue>
          <volume>132</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Haseyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Satomi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Yasukochi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Matsui</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Harada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Uchita</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Nayar S. Treatment of plastic bronchitis. Ann Thorac Surg. 2007; 83 (5): 1884-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Treatment of plastic bronchitis</article-title>
          <source>Ann Thorac Surg</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1884</fpage>
          <lpage>6</lpage>
          <issue>5</issue>
          <volume>83</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nayar</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Association of plastic bronchitis to protein-losing enteropathy after fontan operation</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>We report an unusual case of association of plastic bronchitis (PB) to protein-losing enteropathy (PLE) in a girl of 4 years and 9 months of age with double inlet single left ventricle and ventriculoarterial concordance. submitted to total cavopulmonary surgery. with an intracardiac lateral tunnel at the age of three. The elimination of the 10 cm fibrin bronchial mold (PB) and the alpha-1-antitrypsin elevation of 52 mg/g in feces had both become outstanding. Using sildenafil. the thoracic duct ligature and the cardiac transplant were programmed in case of continuity of the process.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Fontan procedure</kwd>
        <kwd>bronchitis</kwd>
        <kwd>protein-losing enteropathies</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>CASE REPORT</bold>
      </p>
      <p><undefined id="add1-body2"/>Association of plastic bronchitis to protein-losing enteropathy after fontan operation</p>
      <p>
        <bold>Vanessa Alves Guimar&#227;es; Edmar Atik; Jussara Bianchi Castelli; Nana Miura Ikari; Ana Maria Thomaz; Antonio Augusto Barbosa Lopes</bold>
      </p>
      <p>Instituto do Cora&#231;&#227;o (InCor), Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p>We report an unusual case of association of plastic bronchitis (PB) to protein-losing enteropathy (PLE) in a girl of 4 years and 9 months of age with double inlet single left ventricle and ventriculoarterial concordance, submitted to total cavopulmonary surgery, with an intracardiac lateral tunnel at the age of three. The elimination of the 10 cm fibrin bronchial mold (PB) and the alpha-1-antitrypsin elevation of 52 mg/g in feces had both become outstanding. Using sildenafil, the thoracic duct ligature and the cardiac transplant were programmed in case of continuity of the process.</p>
      <p><bold>Key words:</bold> Fontan procedure; bronchitis; protein-losing enteropathies.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>The Fontan operation, though considered the best palliative for univentricular hearts, is accompanied by severe complications, such as plastic bronchitis (PB) and protein-losing enteropathy (PLE), as well as other comorbidities<sup>1</sup>. It is estimated that PLE occurs in a variable percentage of about 1%-13,4%<sup>2,3</sup>. The PLE occurrence is very rarely reported<sup>4-6</sup>, as is the association of these two entities<sup>5</sup>. Therefore, it is our purpose to report this rare association. </p>
      <p>
        <bold>Case report</bold>
      </p>
      <p>A female patient, of 4 years and 9 months of age from S&#227;o Paulo (SP, Brazil), born of a regular term normal birth and daughter of a diabetic mother, has presented early respiratory discomfort and heart murmurs during the first week of life. At that time, the diagnosis was set as a double inlet single left ventricle with ventriculoarterial concordance, interatrial communication (IAC), interventricular communication and arterial channel (AC) persistence, with an important pulmonary hypertension. When one-month-old, the patient was successfully submitted to our services and to the IAC extension by the Rashkind method and, after four days, to the pulmonary trunk bandage and AC closure. At the age of three years and four months, cyanosis and dyspnea were accentuated. </p>
      <p>The hemodynamic study indicated mean arterial pressure of 13 mmHg in the pulmonary artery, of 10 mmHg in the pulmonary capillary, with Qp/Qs = 0.9 and pulmonary vascular resistance of 1.7 WU (Wood unit). Afterwards, the patient was submitted to the total cavopulmonary operation with intracardiac lateral tunnel. Three months after the intervention, the patient presented anasarca, ascites and pleural effusion. Serum albumin was of 1.7 mg/dl. Through a hemodynamic study, the obstruction to the venous flow was discarded. The mean pulmonary artery pressure of both the superior and inferior vena cava was of 15 mmHg, the pulmonary capillary pressure was of 7 mmHg and the Qp/Qs was of 0.8. </p>
      <p>The research result for alpha-1-antitrypsin in feces was of 52 mg/g, confirming the PLE diagnosis. Through the usual measures - hyperproteic, hypofatty diet, along with me medium-chain triglycerides and anticongestives, such as furosemide, spirinolactone and captopril - there was an improvement in the clinical features, obtaining even alpha-1-antitrypsin normality (less than 3 mg/g). Fourteen months after the operation, there was a new decline in the anasarca picture, as well as incessant coughs, cyanosis and fever peak. Serum albumin was of 2.1 mg/dl and alpha-1-antitrypsin was of 13.2 mg/g. The clinical features showed improvement with the usual anticongestive measures within few days. </p>
      <p>Incidentally, during the respiratory physiotherapy exercises the patient expelled a fibrin bronchial mold about 10-centimeter long (<xref ref-type="fig" rid="en_a24fig01-body2">Figure 1</xref>). There was perihilar infiltrate in the thorax radiography, and a hypoattenuanting image in bronchial light in the thorax high-resolution CT scan (<xref ref-type="fig" rid="en_a24fig01-body2">Figure 1</xref>). The anatomopathological report of the bronchial matter was compatible with the PB diagnosis, since it was constituted by compact fibrin combined with numerous lymphoid cells, scarce mucous tissue and permeated by xanthomatous macrophages, besides a focal area with accumulated eosinophils (<xref ref-type="fig" rid="en_a24fig02-body2">Figure 2</xref>).</p>
      <p content-type="asset">
        <fig id="en_a24fig01-body2">
          <graphic xlink:href="1678-4170-abc-94-04-e109-00024-gf01-en.jpg"/></fig>
      </p>
      <p content-type="asset">
        <fig id="en_a24fig02-body2">
          <graphic xlink:href="1678-4170-abc-94-04-e109-00024-gf02-en.jpg"/></fig>
      </p>
      <p>Microscopy and immunohistochemistry excluded the infectious causes (bacteria, alcohol-acid resistant bacilli, viruses and fungi). From the diagnosis of the association of PB with PLE, clinical measurements were instituted to fluidify the airways with inhalations and bronchodilators, as well as furosemide, captopril, spirinolactone and sildenafil. In case of continuity of the process, the ligature of the thoracic duct was programmed, culminating even with a possible cardiac transplant.</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>Currently, the factors involved in the evolutive prognosis after the Fontan operation consist in the making of an adequate communication between the systemic veins and the pulmonary artery, good ventricular performance, normal functioning of atrioventricular valves and normal size of the pulmonary arterial tree. The operation has been undergoing great technical modifications and currently consists mainly in the venous pulmonary systemic connection through the use of an extracardiac tube, more than an intracardiac lateral tunnel, with or without fenestration. The final result provides the patient two serial circulations, the systemic venous return being guided directly to the pulmonary artery without the presence of the ventricular pulsating pump. This &#180;Fontan physiology&#180; submits a patient to a slower venous flow, thus susceptible to the development of chronic pleural effusion, chylothorax, atrial arrhythmia, PLE and PB<sup>4</sup>. </p>
      <p>As for the PB, it constitutes a rare entity. It is characterized by recurring expectoration of peculiar molds from the tracheobronchial tree. Although its etiopathogeny remains unknown, the central venous pressure elevation and the pulmonary and systemic lymphatic system disorders are probable pathogenic mechanisms<sup>5</sup>. The same elements are correlated to PLE, in addition to the fact that, chronically, the low cardiac debt would contribute to the increase of mesenteric vascular resistance. This way, the association between mesenteric hypoperfusion and venous congestion would affect the intestinal mucous membrane. In the presented case, the patient was presented with normal pulmonary pressure, thus excluding part of thus pathogenic mechanism. </p>
      <p>Usually, patients with PB present dyspnea with an increase in ventilatory work, repetitive episodes of coughing and mold elimination, with a predisposition towards respiratory phenomena, such as infection and atelactasias. Thorax radiography usually reveals a peribronchial infiltrate, as well as atelactasias. The molds of bronchial secretion may cause asphyxia, cardiac arrest and death, the latter being reported in up to 29% of patients with this latent condition<sup>6</sup>. </p>
      <p>In PLE, as a result of the enteric loss of serum proteins, there is edema and poor absorption in the intestinal wall, causing diarrhea. In some patients, this process is more insidious and hypoproteinemia may occur in the absence of diarrheic symptoms. The disease typically initiates with corporal edema, evolving with ascites, pleural and pericardial effusion. Laboratory tests reveal low levels of total serum and albumin protein. The gold standard for the diagnosis is an increased intestinal clearance of alpha-1-antitrypsin, a protein produced exclusively in the liver and excreted in small amounts throughout the intestine. The decrease of albumin serum levels reduces the calcium transportation, causing tetany and osteopenia. Hypogammaglobulinemia is another possible disorder, causing immunodeficiency. The early stage of this enteropathy may have serious consequences, resulting in the increase of morbidity and mortality. Two studies have described survival in five years, after the diagnosis of only 50% of patients<sup>3</sup>. </p>
      <p>Many times, the treatment of both conditions is merely symptomatic. In PB, it may be of two types: the inflammatory type, secondary to expressive allergic processes, which may be manipulated with inhalating medication (corticosteroids, azithromycin, urokinase); and the acellular type, prevalent after the Fontan operation, which has been benefitting from the circuit fenestration, the use of pulmonary hypotensor medication, the ligature of the thoracic duct or the cardiac transplant<sup>4,7-10</sup>. In the PLE treatment, there is also another resort: surgically removing the suprahepatic veins. The use of low molecular weight heparin has been described as a remedy to both entities, suggesting it is the same physiopathology<sup>2</sup>. </p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Asociaci&#243;n de bronquitis pl&#225;stica a la enteropat&#237;a perdedora de prote&#237;nas tras operaci&#243;n de fontan</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>Referimos el caso at&#237;pico de asociaci&#243;n de bronquitis pl&#225;stica (BP) con enteropat&#237;a perdedora de prote&#237;nas (EPP) en una menina de 4 a&#241;os y 9 meses de edad, con doble v&#237;a de entrada de ventr&#237;culo &#250;nico tipo izquierdo y concordancia ventr&#237;culo-arterial sometida a la cirug&#237;a cavopulmonar total, con t&#250;nel lateral intracardiaco a los 3 a&#241;os. Se consideraron como llamativas la eliminaci&#243;n de molde bronquial de 10 cm formado por fibrina (BP) y la elevaci&#243;n de alfa-1-antitripsina de 52 mg/g de heces. En uso de sildenafila, se program&#243;, en caso de continuidad del proceso, la ligadura del conducto tor&#225;cico y trasplante card&#237;aco.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>T&#233;cnica de Fontan</kwd>
        <kwd>bronquitis</kwd>
        <kwd>enteropat&#237;as perdedoras de prote&#237;nas</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>CASO CL&#205;NICO</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Asociaci&#243;n de bronquitis pl&#225;stica a la enteropat&#237;a perdedora de prote&#237;nas tras operaci&#243;n de fontan</bold>
          </label>
          <p>
            <bold>Vanessa Alves Guimar&#227;es; Edmar Atik; Jussara Bianchi Castelli; Nana Miura Ikari; Ana Maria Thomaz; Antonio Augusto Barbosa Lopes</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o (InCor), Hospital das Cl&#237;nicas da Faculdade de Medicina da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p>Referimos el caso at&#237;pico de asociaci&#243;n de bronquitis pl&#225;stica (BP) con enteropat&#237;a perdedora de prote&#237;nas (EPP) en una menina de 4 a&#241;os y 9 meses de edad, con doble v&#237;a de entrada de ventr&#237;culo &#250;nico tipo izquierdo y concordancia ventr&#237;culo-arterial sometida a la cirug&#237;a cavopulmonar total, con t&#250;nel lateral intracardiaco a los 3 a&#241;os. Se consideraron como llamativas la eliminaci&#243;n de molde bronquial de 10 cm formado por fibrina (BP) y la elevaci&#243;n de alfa-1-antitripsina de 52 mg/g de heces. En uso de sildenafila, se program&#243;, en caso de continuidad del proceso, la ligadura del conducto tor&#225;cico y trasplante card&#237;aco.</p>
      <p><bold>Palabras clave: </bold> T&#233;cnica de Fontan, bronquitis, enteropat&#237;as perdedoras de prote&#237;nas.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La operaci&#243;n de Fontan, aunque es el mejor paliativo para corazones univentriculares, viene asociada a la evoluci&#243;n de graves complicaciones, como la bronquitis pl&#225;stica (BP) y la enteropat&#237;a perdedora de prote&#237;nas (EPP), adem&#225;s de otras comorbilidades<sup>1</sup>. Se estima que la EPP incida en un porcentaje variable de cerca del 1% a un 13,4%<sup>2,3</sup>. La ocurrencia de BP es referida<sup>4-6</sup> muy raramente, as&#237; como la asociaci&#243;n de estas dos entidades<sup>5</sup>. Por ello, es nuestro prop&#243;sito referir esta asociaci&#243;n at&#237;pica.</p>
      <p>
        <bold>Caso Cl&#237;nico</bold>
      </p>
      <p>Una paciente del sexo femenino, con 4 a&#241;os y 9 meses de edad, natural y procedente de S&#227;o Paulo-SP, nascida de parto normal, a t&#233;rmino, hija de madre diab&#233;tica, present&#243; incomodidad respiratoria precoz y soplo cardiaco auscultado a la primera semana de vida. A la &#233;poca, se estableci&#243; el diagn&#243;stico de doble v&#237;a de entrada de ventr&#237;culo &#250;nico tipo izquierdo con concordancia ventr&#237;culo-arterial, comunicaci&#243;n interatrial (CIA), comunicaci&#243;n interventricular y persistencia de canal arterial (CA), con hipertensi&#243;n pulmonar importante. Con un mes de vida, se someti&#243;, en nuestro servicio y con &#233;xito, a la ampliaci&#243;n de la CIA por el m&#233;todo de Rashkind y, tras 4 d&#237;as, al vendaje del tronco pulmonar y al cierre del CA. Con 3 a&#241;os y 4 meses, hubo acentuaci&#243;n de la cianosis y de la disnea.</p>
      <p>El estudio hemodin&#225;mico revel&#243; presi&#243;n promedio de 13 mmHg en la arteria pulmonar, presi&#243;n promedio de 10 mmHg en el capilar pulmonar, con Qp/Qs = 0,9 y resistencia vascular pulmonar de 1,7 UW. Acto seguido, se someti&#243; a operaci&#243;n cavopulmonar total con t&#250;nel lateral intracardiaco. Despu&#233;s de tres meses de la intervenci&#243;n, estaba en estado de anasarca, ascitis y derrame pleural. La albumina s&#233;rica era de 1,7 mg/dl. Por estudio hemodin&#225;mico, se descart&#243; obstrucci&#243;n al flujo venoso sangu&#237;neo. La presi&#243;n promedio de la arteria pulmonar, de la vena cava superior y de la vena cava inferior era de 15 mmHg, la presi&#243;n capilar pulmonar era de 7 mmHg y el Qp/Qs era de 0,8.</p>
      <p>El resultado de la investigaci&#243;n de alfa-1-antitripsina en las heces fue de 52 mg/g, confirmando el diagn&#243;stico de EPP. Con las medidas usuales, dieta hiperprot&#233;ica, hipograsosa y con triglic&#233;ridos de cadena media al lado de anticongestivos, como furosemida, espironolactona y captopril, hubo mejora del cuadro, consiguiendo incluso la normalidad de alfa-1-antitripsina (menor que 3 mg/g). Tras 14 meses de la operaci&#243;n, hubo nuevo empeoramiento del cuadro de anasarca, adem&#225;s de la incesante aparici&#243;n de cianosis y pico febril. La albumina s&#233;rica era de 2,1 mg/dl y la alfa-1-antitripsina de 13,2 mg/g. El cuadro cl&#237;nico mejor&#243; con mediciones anticongestivas usuales en pocos d&#237;as.</p>
      <p>Incidentalmente, durante los ejercicios de fisioterapia respiratoria, la paciente expeli&#243; molde bronquial formado por fibrina, con cerca de 10 cm de longitud (Figura 1). En la radiograf&#237;a de t&#243;rax hab&#237;a infiltrado perihiliar, y en la tomograf&#237;a computarizada de t&#243;rax de alta resoluci&#243;n, imagen hipoatenuante en la luz bronquial (Figura 1). El laudo anatomopatol&#243;gico del material bronquial era compatible con el diagn&#243;stico de BP, ya que era formado por fibrina compactada y entremezclados con numerosas c&#233;lulas linfoides, con &#225;reas todav&#237;a de tejido mucoide escaso y permeado por macr&#243;fagos xantomatosos, adem&#225;s de &#225;rea focal con acumulaci&#243;n de eosin&#243;filos (Figura 2).</p>
      <p>Microscopia e inmunohistoqu&#237;mica excluyeron causas infecciosas (bacterias, bacilos alcohol-&#225;cido resistentes, virus y fungos). A partir del diagn&#243;stico establecido de la asociaci&#243;n de la BP a la EPP, se instituyeron mediciones cl&#237;nicas de fluidificaci&#243;n de v&#237;as a&#233;reas con inhalaciones y broncodilatadores, adem&#225;s de la furosemida, del captopril, de la espironolactona y del sildenafil. Se program&#243;, en caso de continuidad del proceso, la ligadura del conducto tor&#225;cico, pudiendo llegar incluso a un posible trasplante card&#237;aco.</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>En los d&#237;as actuales, los factores involucrados en el pron&#243;stico evolutivo tras la operaci&#243;n Fontan consisten en llevar a cabo una comunicaci&#243;n adecuada entre las venas sist&#233;micas y la arteria pulmonar, sin obstrucciones y con m&#237;nima p&#233;rdida de energ&#237;a, adem&#225;s de la coexistencia de baja resistencia vascular pulmonar, buen desempe&#241;o ventricular, funcionamiento normal de las v&#225;lvulas atrioventriculares y tama&#241;o normal del &#225;rbol arterial pulmonar. La operaci&#243;n viene sufriendo grandes modificaciones t&#233;cnicas y, en los d&#237;as actuales, consiste predominantemente en la conexi&#243;n venosa sist&#233;mico-pulmonar realizada por tubo extracardiaco, m&#225;s que por t&#250;nel lateral intracardiaco, con o sin ventanaje. El resultado final deja al paciente con dos circulaciones en serie, siendo que el retorno venoso sist&#233;mico se orienta hacia la arteria pulmonar sin la presencia de la bomba puls&#225;til ventricular. Esta "fisiolog&#237;a Fontan" somete a los pacientes a un flujo venoso m&#225;s lento, susceptible as&#237; al desarrollo de efusi&#243;n pleural cr&#243;nica, quilot&#243;rax, arritmias atriales, EPP y BP<sup>4</sup>.</p>
      <p>En cuanto a la BP, se constituye en entidad at&#237;pica. Se caracteriza por expectoraci&#243;n recurrente de peculiares moldes del propio &#225;rbol traqueobr&#243;nquico. Aunque su etiopatogenia sigue desconocida, la elevaci&#243;n de la presi&#243;n venosa central y des&#243;rdenes del sistema linf&#225;tico pulmonar y sist&#233;mico son probables mecanismos patog&#233;nicos<sup>5</sup>. Estos mismos elementos se correlacionan con la EPP, a&#241;adido al hecho de que, cr&#243;nicamente, el bajo gasto cardiaco contribuir&#237;a al aumento de la resistencia vascular mesent&#233;rica. As&#237;, la asociaci&#243;n de hipoperfusi&#243;n mesent&#233;rica con congesti&#243;n venosa afectar&#237;a la integridad de la mucosa intestinal. En el caso presentado, la paciente se hallaba con presi&#243;n pulmonar normal, excluyendo as&#237; parte de este mecanismo patog&#233;nico.</p>
      <p>Usualmente, pacientes con BP presentan disnea con aumento del trabajo ventilatorio, episodios de tos repetitivos y eliminaci&#243;n de los moldes, con predisposici&#243;n a fen&#243;menos respiratorios, como infecci&#243;n y atelectasias. Radiograf&#237;as de t&#243;rax generalmente revelan un infiltrado peribronquial, adem&#225;s de las atelectasias. Los moldes de secreci&#243;n bronquial pueden ocasionar asfixia, parada cardiaca y muerte, que se viene refiriendo en hasta el 29% de los pacientes con esta condici&#243;n latente<sup>6</sup>.</p>
      <p>En la EPP, en consecuencia de la p&#233;rdida ent&#233;rica de prote&#237;nas s&#233;ricas, hay edema y mala absorci&#243;n en la pared intestinal, ocasionando diarrea. En algunos pacientes, este proceso es m&#225;s insidioso y la hipoproteinemia puede producirse en la ausencia de s&#237;ntomas diarreicos. La enfermedad t&#237;picamente se inicia con edema corporal, evolucionando con ascitis, efusi&#243;n pleural y peric&#225;rdica. Las pruebas de laboratorio revelan bajos niveles de prote&#237;na s&#233;rica total y albumina. El <italic>gold standart</italic> para el diagn&#243;stico es un <italic>clearance</italic> intestinal aumentado de alfa-1-antitripsina, prote&#237;na producida exclusivamente en el h&#237;gado y excretada en peque&#241;as cantidades por el intestino. La disminuci&#243;n de los niveles s&#233;ricos de albumina reduce el transporte de calcio, conllevando tetania y osteopenia. Otro disturbio posible es la hipogamaglobulinemia, que acarrea inmunodeficiencia. El inicio de esta enteropat&#237;a puede tener serias consecuencias, resultando en el aumento de morbilimortalidad. Dos estudios describen sobrevida en 5 a&#241;os, tras el diagn&#243;stico de solamente el 50% de los pacientes<sup>3</sup>.</p>
      <p>Muchas veces, el tratamiento de ambas condiciones es solamente sintom&#225;tico. En la BP, puede ser de dos tipos: El tipo inflamatorio, secundario a procesos al&#233;rgicos expresivos, que se puede manejar con medicamentos inhalatorios (corticosteroides, azitromicina, uroquinasa); y el tipo acelular, prevalente tras la operaci&#243;n de Fontan, que se viene beneficiando de la ventanaje del circuito, del uso de medicamentos hipotensores pulmonares, de la ligadura del conducto tor&#225;cico o bien del trasplante cardiaco<sup>4,7-10</sup>. En el tratamiento de la EPP, existe a&#250;n el recurso de exclusi&#243;n quir&#250;rgica de las venas suprahep&#225;ticas. El uso de heparina de bajo peso molecular se viene describiendo como curativo de ambas entidades, lo que sugiere tratarse de la misma fisiopatolog&#237;a<sup>2</sup>.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
